Interaction Checker

Tesamorelin etkileşimleri

Tesamorelin (Egrifta) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 55 belgelenmiş etkileşim var: 0 majör, 23 orta, 32 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Orta düzey etkileşimler (23)

  • Azelastin ve flutikazonantihistaminikOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • BeklometazonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • BetametazonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • BudesonidkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • Budesonid ve formoterolkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • DeflazakortkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • DesonidkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • FludrokortizonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • FlunisolidkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • FluosinonidkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • FlutikazonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • HalobetazolkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • HidrokortizonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • KlobetazolkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • MetilprednizolonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • MometazonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • Olopatadin ve mometazonantihistaminikOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • PrednizolonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • PrednizonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • SiklesonidkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

  • TriamsinolonkortikosteroidOrta

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin etiketi, İlaç etkileşimleri)

Minör değinmeler (32)

  • BrivarasetamantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • Divalproeks (valproat)antikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • EtosüksimidantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • Ezetimib ve simvastatinstatinMinör

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (Tesamorelin etiketi, İlaç etkileşimleri)

  • FelbamatantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • GabapentinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • Kannabidiol (reçeteli)antikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • KlonazepambenzodiazepinMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • LakozamidantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • LamotrijinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • LevetirasetamantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • MetsüksimidantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • PregabalinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • RufinamidantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • SimvastatinstatinMinör

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (Tesamorelin etiketi, İlaç etkileşimleri)

  • TiagabinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • Valproik asitantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • VigabatrinantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

  • ZonisamidantikonvülsanMinör

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Tesamorelin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.